Depression is more than just feeling sad. It’s a medical condition that can severely affect people’s lives, and sometimes, it doesn’t go away even with medication.
This persistent type of depression, where symptoms don’t improve after trying at least two different antidepressants, is known as Treatment-Resistant Depression (TRD).
Given the complex and stubborn nature of TRD, scientists and doctors are always on the lookout for new ways to help people manage it better.
And now, there seems to be a new glimmer of hope through a medication called esketamine.
Understanding TRD: A Sticky Problem
Depression affects millions of people around the world. It is not just feeling blue – it’s a serious medical condition that impacts our mood, thoughts, and body.
People who experience depression might feel constantly sad, lose interest in things they used to enjoy, and find it hard to do everyday activities.
For some, antidepressants and talk therapy can help manage these feelings. But for others, standard treatments just don’t seem to work, which is where TRD comes into play.
People with TRD have tried various treatments, like different kinds of antidepressants, without finding something that helps them feel significantly better.
This is tricky for healthcare providers too, as they want to provide relief to these individuals, but the existing tools in their kit are not doing the trick.
So, researchers have been searching, testing, and trying to find new ways and medicines to tackle TRD. That’s where esketamine, a new player in the field of antidepressant medications, enters the scene.
Esketamine: A New Player on the Field
Esketamine, developed by Janssen, comes as a nasal spray and has been put to the test against TRD in recent research. This medication isn’t entirely new to the medical world, but its use in treating persistent depression is relatively novel.
Esketamine is approved in the USA by the Food and Drug Administration (FDA) and in Europe by the European Medicines Agency (EMA) for its use in depression, and it has shown some impressive results in clinical trials.
A study was set up to compare esketamine with another medication, quetiapine XR, which has also been used to manage TRD in a different way.
Over 600 people participated, trying either esketamine or quetiapine XR, alongside their regular antidepressant medication, for over 32 weeks.
The results brought some fresh, positive news: more people using esketamine found relief from their depressive symptoms compared to those using quetiapine XR.
By the 8-week mark, about 27 out of 100 people using esketamine experienced significant improvement, while about 18 out of 100 did with quetiapine XR.
The Journey Ahead: Hope and Challenges
While this news is encouraging, the journey doesn’t end here. People using esketamine experienced more side effects compared to quetiapine XR, but fewer people stopped using esketamine because of them, which suggests it was generally well-tolerated.
Dr. Albino Oliveira-Maia, who was involved in the study, highlighted a key challenge: making esketamine accessible to those who need it.
Currently, many countries have limited access to approved, scientifically backed treatments for TRD, which includes not only esketamine but also other methods like electroconvulsive therapy and a technique called transcranial magnetic stimulation.
Looking forward, researchers are keen to dive deeper. They want to understand why some people respond to certain treatments while others do not, and they are also interested in exploring how combining different treatments, like esketamine and talk therapy, might further help people manage TRD.
In conclusion, while the esketamine findings are a stride in a positive direction, the real victory will come when these research findings turn into real-world solutions.
It’s crucial that scientific progress is met with solid policy and healthcare practices to ensure that more people can access and benefit from these advancements in depression treatment.
The fight against TRD is certainly not over, but with each new finding, we get a step closer to providing better, more effective help to those who need it.
If you care about mental health, please read studies about 6 foods you can eat to improve mental health, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies about how dairy foods may influence depression risk, and results showing Omega-3 fats may help reduce depression.
The research findings can be found in New England Journal of Medicine.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
